Three years ago, St. Jude Children’s Research Hospital announced the creation of its 2022–27 strategic plan. This bold commitment outlines a plan to accelerate progress in the laboratory, in the clinic and around the globe. Since then, we’ve made gains across the plan’s five focus areas—fundamental science; childhood cancer; pediatric catastrophic diseases; global impact; and infrastructure, talent and culture. Based on what we’ve accomplished in the past year alone, the future is bright with possibilities.
Focus on Fundamental Science
Exploring an endless frontier of possibility
- Elizabeth Hillman, PhD, has been named the inaugural chair of the newly-created Department of Imaging Sciences.
- Babis Kalodimos, PhD, chair of the Department of Structural Biology, has made significant progress on kinase structures and functions since joining St. Jude in 2017. Under his leadership, the Seeing the Invisible in Protein Kinase initiative is a $50 million revolutionary blue-sky research project to study the 500+ human kinases. More than 700 compounds have been identified and the team has now expressed and studied over 130 kinases, with 50-60 studied in detail by NMR.
- The St. Jude Graduate School of Biomedical Sciences began offering a master’s degree in data science, resulting in 140 students across three degree-seeking programs. 42 students earned degrees in 2023.
- Victor Torres, PhD, has been named the inaugural chair of the newly-created Department of Host-Microbe Interactions.
- Steven Varga, PhD, was appointed as the second dean of the St. Jude Graduate School of Biomedical Sciences. He will also oversee a research program and laboratory focused on advancing vaccine development for respiratory syncytial virus (RSV).
- Frank Fazio joined St. Jude as president of the Children’s GMP, LLC, and vice president of therapeutics production and quality.
- Jasmine Plummer, PhD, is leading the new Center for Spatial Omics, a strategic shared resource that will develop cutting-edge spatial omics platforms that reveal how cells interact and organize across multiple dimensions.
- Madan Babu, PhD, a world leader in the application of data sciences to molecular structures, has accepted the appointment to chief data strategist, where he will build out an administrative organization over the ensuing months. This is in conjunction with his leadership in the new Center of Excellence for Data-Driven Discovery.
- Twelve scientists from St. Jude are among investigators named to the 2023 list of Highly Cited Researchers. The list draws from papers that rank in the top 1% of citations.
- The Inspiration4 Advanced Research Center opened to provide laboratory, office and collaborative spaces for more than 1,000 scientists and administrative staff. As of summer 2023, overflow floors have been completed in anticipation of hiring more faculty.
- Top investigator J. Paul Taylor, MD, PhD, was appointed scientific director to guide the institution’s basic science programs and related research efforts.
Focus on Childhood Cancer
Creating a brighter future for children today and generations to come
- The Pediatric Cancer Dependencies Accelerator was created. The purpose of this collaborative project is to transform the scientific understanding of childhood cancers, identify new targets for therapy, and pave the way for new clinical trials and effective treatments. In 2024, PedDep held its third annual retreat, completed numerous whole-genome CRISPR and drug-CRISPR screens, developed new models for high-risk pediatric cancers, and built a dedicated PedDep Accelerator data portal with new pipelines and analytical methods.
- St. Jude has enhanced the clinical trial infrastructure in conjunction with the Department of Oncology and the Comprehensive Cancer Center. They have launched working groups to improve time to move investigator-initiated trials from concept through approvals to implementation. For the first time, St. Jude will be able to run a pediatric cancer trial in multiple countries outside of the US.
- Entrectinib was first given to a human in 2014. In 2024, Dr. Elizabeth Fox, MD, shared that the response rate for children in the US and EU is 65-75%.
- GLOBOTREK is a St. Jude-sponsored clinical trial to treat children <3 years of age who are diagnosed with brain tumors. There are collaborating sites in Brazil, Peru, Egypt, Jordan, and India.
- St. Jude enrolled the first patient in the MemCAR19 study.
- The 100th cellular therapy product was produced by the Children’s GMP, LLC, in conjunction with the Department of Bone Marrow Transplant and Cellular Therapy, Human Applications Lab, and Vector Development team.
- St. Jude Cloud Survivorship Portal launches to handle the amount of data generated from St. Jude LIFE.
- 2024 marks the fifth year of Bringing Chemistry to Medicine, an annual conference hosted on the St. Jude campus and virtually.
- The creation of the Translational Immunology and Immunotherapy Initiative (TI3) will strengthen the St. Jude cancer immunotherapy program. They host an annual conference, the St Jude Annual Translational Cancer Immunotherapy Retreat, now in its fifth year..
- In January 2023, Julie Park, MD, joined St. Jude as chair of the Department of Oncology and the first associate director for translational research on the Comprehensive Cancer Center’s senior leadership team.
- Greg Armstrong, MD, was appointed chair for the Department of Epidemiology and Cancer Control. A physician-scientist, he also serves as the principal investigator of the Childhood Cancer Survivor Study, the world’s largest established resource for survivorship research.
- The Comprehensive Cancer Center is leading one of the largest cancer-focused faculty recruitment efforts in St. Jude history, looking to expand its faculty by 33%.
- The goal of the Center of Excellence in Leukemia Science is to enhance basic and translational research in leukemia and other cancers of the blood and improve outcomes for children with these diseases. Three laboratory-based faculty will lead these efforts in conjunction with an expanded computational and technical staff.
- The translational CAR T-cell therapy program continues to progress, with active CAR T-cell therapy studies for patients with ALL, AML, solid tumors and brain tumors.
- The new Center of Excellence for Pediatric Immuno-Oncology, led by Stephen Gottschalk, MD, and Hongbo Chi, PhD, brings together investigators across Cancer Center programs and academic departments with a mission of harnessing the power of the immune system to help cure incurable pediatric cancers.
- A new clinical trial for relapsed leukemia, led by Seth Karol, MD, will explore the toxicity and potential for therapeutic response in the most aggressive forms of acute lymphoblastic leukemia (ALL).
- The HPV Cancer Prevention Program at St. Jude continues to focus on improving rural HPV vaccination coverage through its Wide Open Spaces campaign. The team also launched the Path to a Bright Future campaign that encourages on-time HPV vaccination.
- The Comprehensive Cancer Center received a two-year Cancer Center Support Grant merit extension from the National Cancer Institute. This is the first time the NCI has offered this two-year extension, which St. Jude was awarded after receiving two consecutive “Exceptional” ratings.
- The institution’s first dedicated clinical trials management system launched, uniting the St. Jude research community under one data platform to manage clinicals trials.
Focus on Childhood Catastrophic Diseases
Giving new hope to children with catastrophic diseases
- Core areas of the Pediatric Translational Neuroscience Initiative continue to grow and thrive, with expanded recruitment, service offerings and program launches. Two major workshops are held annually: One was focused on ultrarare diseases and the other centered on community building and advocacy. In 2024, PTNI enrolled its first fellow.
- Three blue-sky projects have launched, The Partnership to advance development of individualized genomic medicines (PARADIGM), the PTNI Genomic Medicine Initiative (GEMINI) and Tracking the Immune Repertoire of Tumor Lymphocytes (TIRTL).
- In conjunction with scientists from the Broad Institute of MIT and Harvard, Mitch Weiss, MD, PhD, chair of the Department of Hematology, and Jonathan Yen, PhD, director of Therapeutic Genome Engineering, have announced a potentially curative approach for sickle cell disease that uses gene editing that could convert the sickle cell mutation into a normal DNA sequence.
- Opening a telehealth hematology clinic in Tupelo, Mississippi, has allowed St. Jude to better access patients in the region, bridging care for those who have limited access to hematology services.
- A new hematology clinic performs timely assessments of adolescent girls with menorrhagia and severe iron deficiency anemia, allowing St. Jude to rule out the presence of any significant hematological abnormality as a cause of either illness.
- Octavio Ramilo, MD, was appointed chair of the Department of Infectious Diseases. A clinician-scientist, Ramilo is focusing his research on the pathogenesis, effects and treatment of RSV.
- The recently established Center for Experimental Neurotherapeutics enrolled its first patient in the DEVOTE clinical trial, the first interventional study for spinal muscular atrophy at St. Jude.
Focus on Global Impact
Moving science and medicine beyond borders and boundaries
- Global Platform for Access to Childhood Cancer medicines signed between St. Jude and UNICEF will provide safe and effective cancer medicines to approximately 120,000 children.
- Global clinical trial GLOBOTRK protocol approved and under review.
- St. Jude Global celebrated its five-year anniversary. The St. Jude Global Alliance has grown to include 249 medical institutions in 86 countries and more than 76 foundations from 30+ countries.
- The institution’s global efforts will be initially supported by three regional operational hubs, one each in Dubai, UAE; Mexico City, Mexico; and Johannesburg, South Africa, plus an additional location in Geneva, Switzerland. The legal structure of the operational units was also completed.
- DIVIA, a transformative initiative seeking to address major gaps in the diagnosis of childhood cancer using next-generation sequencing technology platforms, was reviewed and approved to move forward.
- SJCARES provides a system to identify, target and monitor health metrics that impact patient outcomes. Over 150 institutions have contributed data to SJCARES, allowing St. Jude Global to understand the depth of disease burden in low- and middle-income countries.
- As the war in Ukraine continues, SAFER Ukraine has focused on sustainability planning, ensuring coordinated support for pediatric cancer patients in Ukraine.
Focus on People and Place
Building a culture, workforce and environment that speeds cures for children
- The patient family badging project launched to increase safety, access, and ease for patients and their families in housing facilities and within the hospital.
- Andrew Smith, MD, PhD, is named the new chair of the Department of Diagnostic Imaging.
- The Hospital Operations and Patient Enterprise (HOPE) Center opens in 2024.
- The Office of Legal Services receives the Corporate Counsel Team Award.
- Plans are announced for the Advanced Research Center II, a 17-story high-rise dedicated to increasing the capacity for groundbreaking research and science.
- Sarah Currie, RNC, MSN, NEA-BC, joins St. Jude as the Chief nursing executive and SVP.
- Brooke Bernhardt, PharmD, joins St. Jude as the Chief pharmaceutical officer.
- Lisa Jordan joins St. Jude as the first SVP of technology commercialization.
- Kate Heffernan, JD, joins St. Jude as the interim research integrity officer.
- Helene Tournu joined St. Jude in 2023 as the senior program manager of the newly formed Prizes and Awards Office within Academic and Biomedical Operations. The team will serve as the key liaison between St. Jude and external awarding organizations.
- Home Care, LLC achieves accreditation from Community Health Accreditation Partners (CHAP) and is the nation’s first to receive the distinction.
- Blue-sky idea to expand expertise of postdoctoral research associates, the SMaRT Plan, launches.
- Blue-sky idea St. Jude Historical Archive is underway with the hire of a lead archivist.
- Planning is underway for a new research building, new parking deck, and renovations to the Kay Kafe.
- Strategic Communications, Education and Outreach (SCEO) continues its successes with the Have More in Memphis campaign, bringing operations in-house and planning for a third issue of Neighborly.
- SCEO has also launched a new Teams app to replace the former St. Jude GO app and reconfigured the use of digital signage on campus.
- The Department of Psychology rebranded as the Department of Psychology and Biobehavioral Sciences to better reflect its focus. Kevin Krull, PhD, was appointed chair.
- After two years and the hard work of hundreds of employees, Workday officially launched on July 1, 2023. Workday is the main home of employee information and a central hub for many employee and manager activities. It will also help align operational services with world-class research and treatment.
- The Domino's Village, the second on-site patient housing facility, opened to families in 2023 after six years of planning, working alongside patients and families and institution-wide collaboration. The Domino’s Village Clinic also opened, featuring a medication-dispensing kiosk.
- In 2023, St. Jude broke ground on two new 15-story towers that will ultimately become the site of the outpatient clinic and clinical office buildings. The construction will take several years and requires the cooperation of several different departments to mitigate logistics, parking, and security.
- St. Jude @ Work is the process of defining a sustainable strategy and corresponding policy for different working models at St. Jude. This is part of the ongoing effort to attract and retain employees and advance Project 2300.
- In 2022, St. Jude began the annual tradition of Heritage Fest, where employees are given the opportunity to share their culture with each other through food, dance, and art. 2024 marks the third year of the festival.
- The Department of Family, Guest & Volunteer Services launched their new FY24-28 departmental strategic plans in 2023 in support of the institutional strategic plan. The departmental strategic plan outlines the direction the Patient Family-Centered Care and Volunteer Services and Special Events teams will go.
- Lori Spicer Robertson was named the institution’s new vice president and chief diversity, equity and inclusion officer. The Office of Diversity, Equity and Inclusion also doubled in size and launched seven new Employee Resource Groups.
- Catherine Corbin was appointed senior vice president and the institution’s first chief business innovation officer. Her focus will be on strategic initiatives and transforming spaces to enhance the organization’s ability to serve patients and families.
- The St. Jude Strategic Plan outlines the recruitment of 2,300 new employees, a 40% workforce increase. Project 2300 includes development of a best-in-class employee recruitment and onboarding program and a focus on improvement in processes to bring top talent to St. Jude and Memphis.
- Both the Office of Large Grant Development and the Conference and Event Management Office were launched in 2023. Sobha Jaishankar, PhD, will lead the former to facilitate proposals of strategic relevance to the institution. Brandi Kirby will oversee a team dedicated to events and event processes geared toward national and global audiences.
- Project IGNITE, the transition process for a new electronic health record system, ensured that the EPIC platform launched in 2022. This new platform will allow St. Jude to improve care, support clinical research, and ensure better clinician experiences.
- The Safe and Sound Academy launched. It aims to improve the quality of care for all children with catastrophic diseases. Staff will have the ability to pursue evidence-based methods to provide the safest care and best outcomes for patients.
- St. Jude launched a comprehensive review and redesign of career paths for employees to provide increased upward mobility and develop long-term career goals. In association with the redesign, salaries were adjusted to enhance competitive position for recruitment and retention.
- The Association for the Health Care Environment recognized St. Jude Environmental Services with a 2022 Certificate of Merit. The Department of EVS, comprised of 225 employees, ensures patients are treated in the cleanest and safest environment possible.
- The Transition Oncology Program, comprised of school advocacy coordinators, nursing professionals, psychologists and social workers, empowers patients and families to navigate the challenges associated with life after cancer. In 2023, the innovative program assisted its 1,000th patient.
- The development and implementation of the Vascular Access Team will improve care, decrease preventable harm and improve the experience that patients and families have during their treatment journey.
- The recently launched Family Rounding Program is a team of dedicated staff that help families and patients feel more engaged and comfortable throughout their health care journeys. A key early success has been maintaining consistent times for rounding and ensuring every person on the care team is present.
- Women in Leadership + Learning, a four-month-long, cohort-based, immersive development experience that aims to empower women, has graduated its first three groups.
- Through the STEMM immersion program, St. Jude hosts Memphis and Shelby County high school students for paid summer internships. The program, now three years old, is designed to expand access to science, technology, engineering and mathematics education for students in the Memphis area.
- Golden retriever Rose is the newest member of the St. Jude Paws at Play program, joining three other facility dogs at St. Jude. Rose enhances psychosocial support for patients and families in several areas, including Social Work, the St. Jude School Program and Family Commons.
- St. Jude recognizes that postdoctoral researchers are an essential component of the research mission. First-year salaries for basic lab postdocs increased nearly $15,000 while data science postdocs saw an increase of nearly $30,000 annually.
- Once again, St. Jude has placed atop U.S. News & World Report’s list of top pediatric cancer hospitals, earning a ranking of No. 5 in 2023.
- The Family Commons, a 45,000 square-foot space for patients and families to relax, opened in February 2023. The space houses the St. Jude School Program, an art room and science lab, indoor and outdoor play areas, a café, private rooms for families and a sacred space, among other amenities.
- Over 1,000 employees have relocated to the Peabody Place campus in downtown Memphis as renovations take place on the main campus.
Selected scientific and medical publications
Emerging from FY22-27 St. Jude Strategic Plan
-
Base editing shows potential superiority for curing sickle cell disease
07/03/2023
Adenosine base editing restarted fetal hemoglobin expression in cells from patients with sickle cell disease. Find how St. Jude & Broad are advancing to a cure.
-
St. Jude finds NLRP12 as a new drug target for infection, inflammation and hemolytic diseases
06/01/2023
NLRP12 bridges hemolysis, inflammation and multi-organ damage. Learn how this ‘on’ switch for innate immune cell death could be a drug target to prevent pathology.
-
Genetic change increased bird flu severity during U.S. spread
05/30/2023
Find how H5N1 avian influenza viruses increased disease-causing abilities & gained the capability to enter mammalian brains as they spread west across North America.
-
SWI/SNF complexes “bookmark” cell identity during division
05/24/2023
Read about how Scientists at St. Jude determined how the SWI/SNF chromatin remodeling complex helps cancer cells remember how to be cancerous after division.
-
Epigenetic landscape modulates pioneer transcription factor binding
05/24/2023
St. Jude scientists are studying how pioneer transcription factors access tightly wound DNA. Learn about how their findings may impact therapeutic development.
-
Clinical trial improves neurocognitive outcomes for childhood craniopharyngioma
04/18/2023
Proton therapy for craniopharyngioma had better neurocognitive than & similar survival outcomes as historical photon therapy. Read the phase 2 clinical trial.
-
Healthy lifestyle associated with reduced mortality risk in childhood cancer survivors
04/05/2023
A report from the Childhood Cancer Survivor Study (CCSS) provides strong evidence of the importance of a healthy lifestyle for adults who were treated for cancer as children
-
Humans vs. Bacteria: Differences in Ribosome Decoding Revealed
04/05/2023
St. Jude scientists found that human ribosomes decode mRNA slower but more accurately than bacteria. Read about the study’s implications for drug development.
-
Method for improving seasonal flu vaccines also aids pandemic prediction
03/29/2023
Influenza (flu) vaccines and pandemic predictions can be improved; learn how St. Jude scientists found impactful hemagglutinin mutations contributing to both.
-
Integrated structural biology provides new clues for cystic fibrosis treatment
03/22/2023
Learn about how the cystic fibrosis transmembrane conductance regulator works and how findings from St. Jude will help therapeutic development.
-
Detect minor clones in blood cells: St. Jude looks deep to find source of accelerated aging in childhood cancer survivors
02/08/2023
Explore how deep sequencing childhood cancer survivors found the mutational fingerprint of a toxic chemotherapy associated with a marker of accelerated aging.
-
St. Jude scientists create more efficient CAR immunotherapies using a molecular anchor
02/02/2023
Discover how chimeric antigen receptors (CARs) with a new anchor domain increased anti-cancer activity of cellular immunotherapies in cancer models.
-
Structural insights reveal how SPOP protein contributes to cancer
01/23/2023
St. Jude scientists have captured the 3D structure of the SPOP protein, revealing how it contributes to cancer. Read about the implications for therapeutics.
-
Pharmacotyping of childhood leukemia provides a blueprint for ‘true precision medicine’
01/05/2023
St. Jude scientists performed the largest study yet examining drug sensitivity in childhood acute lymphoblastic leukemia across genomic subtypes and its association with treatment response.
-
A link between hypoxia and fetal hemoglobin provides hope for sickle cell disease
10/12/2022
Cellular response to low oxygen also increases fetal hemoglobin expression in adults, which could lead to novel treatments for some genetic anemias.
-
Health inequity may drive higher symptom burden in childhood cancer survivors
09/27/2022
Findings from St. Jude Children’s Research Hospital reveal that childhood cancer survivors with disadvantaged socio-demographic factors are over 7 times more likely to experience severe symptom burdens.
-
Findings explain exceptional auditory abilities in Williams-Beuren Syndrome
09/23/2022
St. Jude scientists identified the mechanism by which Williams-Beuren Syndrome enhances the ability to discriminate between sounds as interneuron hyperexcitability in the auditory cortex.
-
Rhombic lip implicated in origins of high-risk medulloblastoma
09/21/2022
St. Jude scientists found that group 3 and 4 medulloblastoma arise from the rhombic lip, knowledge that may help improve research models and therapeutic development.
-
To wipe childhood cancer off the map, scientists must chart its genomic landscape
09/01/2022
St. Jude scientists sequenced the most childhood cancer samples from a single cancer type ever in a landmark study.
-
New chemical technology leads to better targeted therapeutics against high-risk leukemia in the lab
08/24/2022
St. Jude scientists created an LCK targeted PROTAC able to kill T-cell acute lymphoblastic leukemia cells.